← AbbVie Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $25.6b |
$28.2b
+10.06%
|
$32.8b
+16.08%
|
$33.3b
+1.57%
|
$45.8b
+37.69%
|
$56.2b
+22.69%
|
$58.1b
+3.30%
|
$54.3b
-6.44%
|
$56.3b
+3.71%
|
$61.2b
+8.57%
|
$64.4b
+5.27%
|
|
| Cost of Revenue | $5.8b |
$7.0b
+20.69%
|
$7.7b
+9.63%
|
$7.4b
-3.61%
|
$15.4b
+106.84%
|
$17.4b
+13.38%
|
$17.4b
-0.18%
|
$20.4b
+17.23%
|
$16.9b
-17.20%
|
$18.2b
+7.69%
|
$18.4b
+0.88%
|
|
| Cost of products sold | $5.8b |
$7.0b
+20.69%
|
$7.7b
+9.63%
|
$7.4b
-3.61%
|
$15.4b
+106.84%
|
$17.4b
+13.38%
|
$17.4b
-0.18%
|
$20.4b
+17.23%
|
$16.9b
-17.20%
|
$18.2b
+7.69%
|
— | |
| Gross Profit (Calculated) | $19.8b |
$21.2b
+6.92%
|
$25.0b
+18.22%
|
$25.8b
+3.16%
|
$30.4b
+17.77%
|
$38.8b
+27.40%
|
$40.6b
+4.87%
|
$33.9b
-16.58%
|
$39.4b
+16.30%
|
$43.0b
+8.94%
|
— | |
| Research and development | $4.4b | $5.0b | $10.3b | $6.4b | $6.6b | $7.1b | $6.5b | $7.7b | $12.8b | $9.1b | $9.7b | |
| Selling, General and Administrative Expense | $5.9b | $6.3b | $7.4b | $6.9b | $11.3b | $12.3b | $15.3b | $12.9b | $14.8b | $14.0b | $14.7b | |
| Amortization of Intangible Assets | $764.0m | $1.1b | $1.3b | $1.6b | $5.8b | $7.7b | $7.7b | $7.9b | $7.6b | $7.4b | — | |
| Operating Income (Loss) | $9.4b |
$9.6b
+2.22%
|
$6.4b
-33.45%
|
$13.0b
+103.40%
|
$11.4b
-12.48%
|
$17.9b
+57.74%
|
$18.1b
+1.08%
|
$12.8b
-29.59%
|
$9.1b
-28.38%
|
$15.1b
+64.99%
|
$21.9b
+44.94%
|
|
| Other Operating Income (Expense), Net | — | $0 | $500.0m | $890.0m | $0 | ($432.0m) | ($56.0m) | $179.0m | $7.0m | $241.0m | — | |
| Interest Expense | $1.0b | $1.1b | $1.3b | $1.8b | $2.5b | $2.4b | $2.2b | $2.2b | $2.8b | $2.9b | $2.9b | |
| Interest expense, net | $965.0m | $1.0b | $1.1b | $1.5b | $2.3b | $2.4b | $2.0b | $1.7b | $2.2b | $2.6b | $2.9b | |
| Foreign Currency Transaction Gain (Loss), before Tax | ($303.0m) | ($348.0m) | ($24.0m) | ($42.0m) | ($71.0m) | ($51.0m) | ($148.0m) | ($146.0m) | ($21.0m) | ($58.0m) | — | |
| Other Expenses | — | — | $500.0m | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | ($232.0m) | ($513.0m) | ($18.0m) | ($3.0b) | ($5.6b) | ($2.5b) | ($2.4b) | ($4.7b) | ($3.2b) | ($5.8b) | — | |
| Other expense, net | $232.0m | $513.0m | $18.0m | $3.0b | $5.6b | $2.5b | $2.4b | $4.7b | $3.2b | $5.8b | — | |
| Interest Income (Expense), Nonoperating, Net | ($965.0m) | ($1.0b) | ($1.1b) | ($1.5b) | ($2.3b) | ($2.4b) | ($2.0b) | ($1.7b) | ($2.2b) | ($2.6b) | $270.0m | |
| Earnings before income tax expense | $7.9b | $7.7b | $5.2b | $8.4b | $3.4b | $13.0b | $13.5b | $6.2b | $3.7b | $6.6b | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($1.7b) | ($2.7b) | ($4.3b) | ($2.8b) | ($4.5b) | ($1.6b) | ($4.6b) | ($3.5b) | ($7.7b) | ($3.5b) | $8.7b | |
| Current Income Tax Expense (Benefit) | $2.7b | $6.6b | $1.0b | $422.0m | $1.1b | $2.3b | $3.6b | $4.3b | $879.0m | $2.9b | $2.4b | |
| Income Tax Expense (Benefit) | $1.9b | $2.4b | ($490.0m) | $544.0m | ($1.2b) | $1.4b | $1.6b | $1.4b | ($570.0m) | $2.4b | $2.4b | |
| Net earnings | — | — | $5.7b |
$7.9b
+38.60%
|
$4.6b
-41.36%
|
$11.5b
+149.87%
|
$11.8b
+2.56%
|
$4.9b
-58.86%
|
$4.3b
-12.05%
|
$4.2b
-1.24%
|
$6.3b
+48.12%
|
|
| Net earnings attributable to AbbVie Inc. | $6.0b | $5.3b | $5.7b | $7.9b | $4.6b | $11.5b | $11.8b | $4.9b | $4.3b | $4.2b | — | |
| Net Income (Loss) Attributable to Parent | $6.0b |
$5.3b
-10.82%
|
$5.7b
+7.12%
|
$7.9b
+38.60%
|
$4.6b
-41.44%
|
$11.5b
+150.04%
|
$11.8b
+2.55%
|
$4.9b
-58.91%
|
$4.3b
-12.03%
|
$4.2b
-1.22%
|
$6.3b
+48.37%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | $5.9b |
$5.3b
-10.81%
|
$5.7b
+7.08%
|
$7.8b
+38.62%
|
$4.6b
-41.90%
|
$11.5b
+151.71%
|
$11.8b
+2.74%
|
$4.8b
-59.09%
|
$4.2b
-12.07%
|
$4.2b
-1.23%
|
$6.3b
+49.78%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | $0 | $0 | $6.0m | $7.0m | $9.0m | $10.0m | $8.0m | $7.0m | $6.3b | |
| Net earnings attributable to noncontrolling interest | — | — | $0 | $0 | $6.0m | $7.0m | $9.0m | $10.0m | $8.0m | $7.0m | — | |
| Earnings Per Share, Basic | $3.65 | $3.31 | $3.67 | $5.30 | $2.73 | $6.48 | $6.65 | $2.73 | $2.40 | $2.37 | $3.54 | |
| Earnings Per Share, Diluted | $3.63 | $3.30 | $3.66 | $5.28 | $2.72 | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 | $3.54 | |
| Common Stock, Dividends, Per Share, Declared | $2.35 | $2.63 | $0.00 | $4.39 | $4.84 | $5.31 | $5.71 | $5.99 | $6.29 | $6.65 | — | |
| Weighted Average Number of Shares Outstanding, Basic | 1.6b | 1.6b | 1.5b | 1.5b | 1.7b | 1.8b | 1.8b | 1.8b | 1.8b | 1.8b | 1.8b | |
| Weighted-average basic shares outstanding (in shares) | 1.6b | 1.6b | 1.5b | 1.5b | 1.7b | 1.8b | 1.8b | 1.8b | 1.8b | 1.8b | — | |
| Weighted-average diluted shares outstanding (in shares) | 1.6b | 1.6b | 1.5b | 1.5b | 1.7b | 1.8b | 1.8b | 1.8b | 1.8b | 1.8b | — | |
| Weighted Average Number of Shares Outstanding, Diluted | 1.6b | 1.6b | 1.5b | 1.5b | 1.7b | 1.8b | 1.8b | 1.8b | 1.8b | 1.8b | 1.8b | |
| Additional Financial Items | ||||||||||||
| Acquired IPR&D and milestones | $200.0m | $327.0m | $424.0m | $385.0m | $1.2b | $962.0m | $697.0m | $778.0m | $2.8b | $5.0b | — | |
| Costs and Expenses | $16.3b | $18.6b | $26.4b | $20.3b | $34.4b | $38.3b | $39.9b | $41.6b | $47.2b | $46.1b | — | |
| Net foreign exchange loss | $303.0m | $348.0m | $24.0m | $42.0m | $71.0m | $51.0m | $148.0m | $146.0m | $21.0m | $58.0m | — | |
| Operating earnings | $9.4b |
$9.6b
+2.22%
|
$6.4b
-33.45%
|
$13.0b
+103.40%
|
$11.4b
-12.48%
|
$17.9b
+57.74%
|
$18.1b
+1.08%
|
$12.8b
-29.59%
|
$9.1b
-28.38%
|
$15.1b
+64.99%
|
— |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.